Long-Term Use of Low-Dose Aspirin can Reduce Multiple Gastrointestinal Cancer Incidence and Mortality: A 10-Year Population-Based Study

2017 ◽  
Vol 152 (5) ◽  
pp. S142
Author(s):  
Kelvin Tsoi ◽  
Felix C.H. Chan ◽  
Hoyee W. Hirai ◽  
Joseph J. Sung
Keyword(s):  
Cancer Incidence ◽  
Gastrointestinal Cancer ◽  
Low Dose ◽  
Population Based ◽  
Population Based Study ◽  
Dose Aspirin ◽  
Incidence And Mortality ◽  
Low Dose Aspirin

Comparing mortality of colorectal cancer and gastrointestinal bleeding among patients with long-term use of low dose aspirin: A population-based study of 689,209 patients.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 527-527
Author(s):  
Joseph Sung ◽  
Kelvin Kf Tsoi
Keyword(s):  
Colorectal Cancer ◽  
Gastrointestinal Bleeding ◽  
Large Scale ◽  
Low Dose ◽  
Population Based ◽  
Dose Aspirin ◽  
Increased Risk ◽  
Incidence And Mortality ◽  
Low Dose Aspirin

527 Background: Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, is well-known to protect against colorectal cancer (CRC) development but increase risk of gastrointestinal bleeding (GIB). Few large-scale studies have compared the benefit and risk of long-term aspirin usage. This cohort study aims to evaluate the use of low-dose aspirin to prevent CRC and the risk of GIB associated with the aspirin use. Methods: A population-based clinical dataset was used to compare incidence and mortality of CRC and GIB patients receiving low-dose aspirin with sex-and-age matched controls (in 1:2 ratio). Patients with aspirin≤6 months were excluded. Clinical data of 206,243 aspirin users (mean dose 80 mg/day, mean duration 7.7 years) and 482,966 non-users were included. All patients must have at least 10-year follow up on clinical outcome. Results: Among aspirin users 5,776 (2.80%) were diagnosed with CRC; 2,097 (1.02%) died of the malignancy. 16,483 (3.41%) non-users were diagnosed with CRC; 7,963 (1.65%) died of CRC. Using the cox-proportional hazard regression, aspirin usage showed a modest but significant reduction in CRC mortality (HR = 0.65; 95% CI = 0.62 to 0.69). On the other hand, 11,187 (5.42%) aspirin users developed GIB, and 841 (0.41%) died. 15,186 (3.14%) non-users developed GIB, and 1,682 patients (0.35%) died. Aspirin users showed modest but significant increased risk of GIB-related mortality (HR = 1.24; 95% CI = 1.14 to 1.35). Conclusions: The long-term use of low dose aspirin shows preventive effect on CRC, but also increases the associated GIB risk. Considerations of prophylactic use of aspirin should balance the benefit and the risk of this treatment to the target population. [Table: see text]

scholarly journals Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden

BMJ Open ◽  
2018 ◽  
Vol 8 (7) ◽  
pp. e021869 ◽  
Author(s):  
Nele Brusselaers ◽  
Jesper Lagergren
Keyword(s):  
Gastrointestinal Cancer ◽  
Low Dose ◽  
Population Based ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Cancer Types ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Cox 2 Inhibitors

ObjectivesAspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are potential candidates for chemoprevention of gastrointestinal cancer. We aimed to assess the association between contemporary NSAID use (≥180 days) and gastrointestinal cancer.DesignNationwide Swedish population-based cohort study (2005–2012).SettingSwedenParticipantsAll adults exposed to maintenance NSAIDs use (aspirin, n=783 870; unselective NSAIDs, n=566 209, selective cyclo-oxygenase (COX)-2 inhibitors, n=17 948) compared with the Swedish background population of the same age, sex and calendar period.Outcome measuresThe risk of different gastrointestinal cancer types expressed as standardised incidence ratios (SIR) and 95% CIs, taking into account concurrent proton pump inhibitors (PPIs) and statins usage.ResultsThe SIR for gastrointestinal cancer for aspirin use was 1.02 (95% CI 1.00 to 1.04), with clearly reduced risk for long-term users (SIR=0.31, 95% CI 0.30 to 0.33 for 5.5–7.7 years), but an increased risk for short-term users (SIR=2.77, 95% CI 2.69 to 2.85), and stronger protective effect for low-dose aspirin (SIR=0.86, 95% CI 0.85 to 0.88). Users of non-selective NSAIDs showed an overall decreased risk of gastrointestinal cancer (SIR=0.79, 95% CI 0.77 to 0.82), in particular for cancer of the stomach, colorectum and oesophagus, and the SIRs were further decreased among long-term users. Users of selective COX-2 inhibitors showed a SIR=0.89 (95% CI 0.73 to 1.09) for gastrointestinal cancers. Both aspirin and unselective NSAIDs users who also were using PPIs, had higher risks for all gastrointestinal cancer types; and lower risk if using statins.ConclusionLong-term use of (low-dose) aspirin and non-selective NSAIDs was associated with a decreased risk of all gastrointestinal cancer types.

scholarly journals Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study

2019 ◽  
Vol 30 ◽  
pp. v259
Author(s):  
L. Garcia Rodriguez ◽  
P. Vora ◽  
M. Soriano-Gabarró ◽  
L. Cea Soriano
Keyword(s):  
Oesophageal Cancer ◽  
Low Dose ◽  
Population Based ◽  
Population Based Study ◽  
Dose Aspirin ◽  
Low Dose Aspirin

scholarly journals Alarmingly poor adherence to low-dose aspirin: a large population-based study

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P2522-P2522 ◽  
Author(s):  
G. Singh ◽  
G. Arora ◽  
A. Mannalithara ◽  
A. Mithal ◽  
A. Sehgal ◽  
...  
Keyword(s):  
Low Dose ◽  
Large Population ◽  
Population Based ◽  
Poor Adherence ◽  
Population Based Study ◽  
Dose Aspirin ◽  
Low Dose Aspirin

scholarly journals Association Between Aspirin Use and Decreased Risk of Pneumonia in Patients With Cardio-Cerebra-Vascular Ischemic Disease: A Population-Based Cohort Study

2021 ◽  
Vol 9 ◽  
Author(s):  
Ying-Cheng Chen ◽  
Yin-Yang Chen ◽  
Han Wei Yeh ◽  
Tung-Ying Yeh ◽  
Jing-Yang Huang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Low Dose ◽  
Population Based ◽  
Hazard Ratio ◽  
Cumulative Probability ◽  
Research Database ◽  
Cox Regression Analysis ◽  
Dose Aspirin ◽  
Low Dose Aspirin

This study evaluated the association between long-term low-dose aspirin use and decreased risk of pneumonia in patients with cardio-cerebra-vascular ischemic diseases (CCVDs). This retrospective cohort study used records from Taiwan's National Health Insurance Research Database of claims made between 1997 and 2013. After propensity score matching (PSM), patients who took a low dose of aspirin for more than 90 days within 1 year of diagnosis with CCVDs were identified as the exposure group (n = 15,784). A matched total of 15,784 individuals without aspirin use were selected for the non-aspirin group. The main outcome was the development of pneumonia after the index date. Multivariable Cox regression analysis and Kaplan–Meier survival analysis were performed to estimate the adjusted hazard ratio (aHR) and cumulative probability of pneumonia. The result after PSM indicated a lower hazard ratio for pneumonia in aspirin users (aHR = 0.890, 95% confidence interval = 0.837–0.945). Therefore, patients with CCVDs who took aspirin had a lower risk of developing pneumonia than those who did not. In conclusion, this population-based cohort study demonstrated that long-term low-dose aspirin use is associated with a slightly decreased risk of pneumonia in patients with CCVDs.

scholarly journals Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study

2016 ◽  
Vol 48 (2) ◽  
pp. 798-805 ◽  
Author(s):  
Young-Il Kim ◽  
So Young Kim ◽  
Ji Hyun Kim ◽  
Jun Ho Lee ◽  
Young-Woo Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Cancer Incidence ◽  
Low Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin
Sign in / Sign up

Export Citation Format

Share Document